Bosentan improved persistent pulmonary hypertension in a case after implantation of a left ventricular assist device

作者：Imamura Teruhiko^*; Kinugawa Koichiro; Hatano Masaru; Kato Naoko; Minatsuki Shun; Muraoka Hironori; Inaba Toshiro; Maki Hisataka; Shiga Taro; Yao Atsushi; Kyo Shunei; Ono Minoru; Nagai Ryozo

来源：Journal of Artificial Organs, 2013, 16(1): 101-104.

DOI：10.1007/s10047-012-0662-4

• Out of proportion
• Postcapillary
• Endothelin receptor antagonist

No medical treatment has been established to ameliorate pulmonary hypertension (PH) due to left heart disease. Heart transplantation (HTx) is thus far the definitive therapy for stage D heart failure, but concomitant PH is one of the major risk factors for death after HTx. Recently, implantation of a left ventricular assist device (LVAD) has been reported to improve PH and has become a major bridge tool for HTx. We experienced a rare case with persistent PH even after the implantation of a continuous-flow LVAD. The administration of an endothelin receptor antagonist, bosentan, significantly decreased pulmonary vascular resistance. Combination therapy with LVAD implantation and anti-PH medication may be useful for patients with stage D heart failure complicated with severe PH.

• 出版日期2013-3